Takeda money

27 Apr 2018 By Neil Unmack

The $62 bln Takeda bid should in theory be an attractive hedge-fund plaything. A yawning gap between the offer value and the target’s share price suggests otherwise. Multiple currencies and time zones act as deterrents. So too do the scars from Shire’s deal with AbbVie.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)